UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 20,
2022
Femasys
Inc.
(Exact name of registrant as specified in its charter)
|
Delaware
|
001-40492
|
11-3713499
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
3950 Johns Creek Court, Suite 100
Suwanee, Georgia
|
|
30024
|
|
(Address of principal executive offices)
|
|
(Zip
Code)
|
(770) 500-3910
(Registrant’s telephone number, including area code)
n/a
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instructions
A.2. below):
☐
|
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐ |
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Exchange
Act:
|
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
|
Common Stock, par value $0.001 per share
|
|
FEMY
|
|
The
Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§
230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☒
|
Item 7.01 |
Regulation FD
Disclosure
|
On October 20, 2022, Femasys Inc. (the “Company”) posted on its
website an updated slide presentation, which is attached as Exhibit
99.1 to this Current Report on Form 8-K and incorporated by
reference herein. Representatives of the Company will use the
presentation in various meetings with investors, analysts and other
parties from time to time.
The information furnished in this Item 7.01 and Exhibit 99.1
attached hereto is being furnished and shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934,
as amended, or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference into any
filing under the Securities Act of 1933, as amended, except as may
be expressly set forth by specific reference in such filing.
The Company expressly disclaims any obligation to update or revise
any of the information contained in the corporate
presentation.
On October 20, 2022, Femasys Inc. (the “Company”) announced a
strategic update on its FemaSeed® pivotal trial design to expedite
clinical program advancement. A copy of the press release is being
furnished as Exhibit 99.2 to this Current Report on Form 8-K and is
incorporated herein by reference.
|
Item 9.01 |
Financial
Statements and Exhibits.
|
|
Exhibit
No.
|
Description
|
|
|
|
|
|
Femasys Inc.
Corporate Presentation dated October 2022
|
|
|
Press Release
of Femasys Inc. dated October 20, 2022.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
Femasys
Inc.
|
|
|
|
|
|
|
By:
|
|
|
|
Names: Kathy
Lee-Sepsick
|
|
|
Title: Chief
Executive Officer
|
Date: October 20, 2022